Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

  • Revenue in USD (TTM)43.73bn
  • Net income in USD6.77bn
  • Incorporated1994
  • Employees99.41k
  • Location
    Sanofi SA54 rue la BoetiePARIS 75008FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
announced
Transaction
value
Kadmon Holdings IncAnnounced08 Sep 202108 Sep 2021Announced-2.12%1.76bn
Translate Bio IncDeal completed03 Aug 202103 Aug 2021Deal completed-1.89%3.04bn
Tidal Therapeutics IncDeal completed09 Apr 202109 Apr 2021Deal completed0.47%470.00m
Kymab Group LtdDeal completed11 Jan 202111 Jan 2021Deal completed8.02%1.45bn
Kiadis Pharma NVDeal completed02 Nov 202002 Nov 2020Deal completed10.00%254.17m
Data delayed at least 15 minutes, as of Oct 22 2021 16:39 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.